2-Ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]benzoic acid

Catalog No. :
ACGVIT350
CAS No. :
194602-23-8
Molecular Formula :
C14H20N2O5S
Molecular Weight :
328.39

IUPAC Name:2-ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)benzoic acid

2-Ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]benzoic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$601.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-Ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]benzoic acid
IUPAC Name2-ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)benzoic acid
MDL No.MFCD06411140
Molecular FormulaC14H20N2O5S
Molecular Weight328.39
SMILESO=C(O)C1=CC(S(=O)(N2CCN(C)CC2)=O)=CC=C1OCC
InChI KeyTXKSEEXWAGLOIY-UHFFFAOYSA-N
Synonym2-ETHOXY-5-[(4-METHYLPIPERAZIN-1-YL)SULFONYL]BENZOIC ACID;2-Ethoxy-5-[(4-methyl-1-piperazinyl;Benzoic acid, 2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]-;Sildenafil Impurity 61;Sildenafil intermediate 2;5-(2-Hydroxyphenyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
CAS No.194602-23-8

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACGVIT350 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACPKDN746 route compound structure diagram
    ACPKDN746200575-16-2 In Stock
  2. Plus
  3. ACJACD865 route compound structure diagram
    ACJACD86534352-59-5 In Stock
  4. Then
  5. ACGVIT350 route product structure diagram
    ACGVIT350194602-23-8
Inquiry

2. ACGVIT350 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACGVIT350 route product structure diagram
    ACGVIT350194602-23-8
Inquiry

Comments (0)